Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term
Eli Lilly's biotech strategy calls for the creation of a pipeline that will yield one new biotechnology-based drug launch each year beginning in 2011, the company announced
You may also be interested in...
The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.
We never meant to sell ImClone right away, and we don’t intend to flip Biogen Idec if we win the proxy fight, Icahn director says.
Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it